Given that the hACE2 receptor, targeted by the S protein of SARS-CoV-2 to initiate infection, is highly expressed in the nasal and oral mucosa [40], intranasal or intraoral delivery of antiviral agents could be a valuable strategy in stopping the spread of the virus. The gene discussed is PROS1; the disease is infection.